Brown Advisory Inc. Lowers Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Brown Advisory Inc. trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,385 shares of the biopharmaceutical company's stock after selling 2,495 shares during the period. Brown Advisory Inc.'s holdings in Alnylam Pharmaceuticals were worth $8,475,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Jones Financial Companies Lllp purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $63,000. Atria Investments Inc lifted its position in Alnylam Pharmaceuticals by 5.3% during the 4th quarter. Atria Investments Inc now owns 3,311 shares of the biopharmaceutical company's stock valued at $779,000 after acquiring an additional 166 shares during the period. Proficio Capital Partners LLC lifted its position in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock valued at $45,570,000 after acquiring an additional 192,916 shares during the period. Finally, Larson Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded up $0.81 during trading hours on Monday, hitting $315.75. 629,558 shares of the company's stock traded hands, compared to its average volume of 854,540. The business's fifty day moving average price is $301.17 and its two-hundred day moving average price is $269.13. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market capitalization of $41.17 billion, a P/E ratio of -151.08 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent analyst reports. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price for the company. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, UBS Group lifted their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $345.70.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.